Registry for HER2-positive breast cancer patients

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study aims to gather data on patients with HER2-positive breast cancer to explore the relationships between various patient and tumor characteristics and their outcomes. By collecting and analyzing this information, researchers hope to identify patterns that could inform treatment decisions and improve patient care. The study will include patients at different stages of HER2-positive breast cancer, allowing for a comprehensive understanding of the disease.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Stage I-IV HER2-positive breast cancer

Exclusion Criteria:

* None

Where it's running

• The University of Kansas Cancer Center
  Westwood, Kansas, United States Recruiting
• KUCC - Indian Creek
  Overland Park, Kansas, United States Active not recruiting
• KUCC - Overland Park
  Overland Park, Kansas, United States Active not recruiting
• KUCC - Briarcliff
  Westwood, Kansas, United States Active not recruiting
• KUCC - Olathe
  Westwood, Kansas, United States Active not recruiting
• KUCC - Lee's Summit
  Lee's Summit, Missouri, United States Active not recruiting

Study contacts

• Study coordinator: Study Coordinator
• Email: PRO-HER2@kumc.edu
• Phone: 913-588-6079

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Evaluating PC14586 for advanced solid tumors with a specific mutation

  This study is testing a new oral medication called PC14586 to see if it can help people with advanced solid tumors that have a specific mutation in the TP53 gene.

  Recruiting at 71 sites Phase 1/2 PMV Pharmaceuticals, Inc · Irvine, California and 75 other locations · NCT04585750

• Oral paclitaxel with anti-HER2 therapy in HER2-positive breast cancer before surgery

  This trial tests a paclitaxel oral solution given with trastuzumab and pertuzumab to see if a safe dose can be found for women with HER2-positive breast cancer before they have surgery.

  Recruiting Phase 1/2 The Affiliated Hospital Of Guizhou Medical University · Guiyang, Guizhou · NCT07739511

• Olaparib with Trastuzumab and Pertuzumab before surgery for older women with HER2-positive breast cancer

  This trial tests whether adding olaparib to standard HER2-targeted therapy can help older women with newly diagnosed, operable HER2-positive breast cancer before surgery.

  Recruiting Phase 4 Zhejiang Cancer Hospital · Hangzhou, Zhejiang · NCT07695259

• Pyrotinib-based regimens for advanced HER2-positive breast cancer: real-world sequential therapy after progression

  This real-world study tests whether giving disitamab vedotin after pyrotinib-based treatment helps people with advanced HER2-positive breast cancer.

  Recruiting Phase 4 Peking University People's Hospital · Beijing, Beijing Municipality · NCT07600164

• Pre-surgery trastuzumab deruxtecan (SHR-A1811) plus pertuzumab for HER2-positive breast cancer

  This trial tests giving trastuzumab deruxtecan (SHR-A1811) with pertuzumab before surgery to see if it helps women with stage II–III HER2-positive breast cancer achieve a complete response.

  Recruiting Phase 2 Shanghai Jiao Tong University School of Medicine · Shanghai, Shanghai Municipality · NCT07393425

• HLX22 plus HLX87 as first-line treatment for HER2-positive recurrent or metastatic breast cancer

  This will test whether combining HLX22 with HLX87 helps adults with HER2-positive recurrent or metastatic breast cancer when given as a first-line treatment.

  Recruiting Phase 2/3 Shanghai Henlius Biotech · Beijing, Beijing Municipality · NCT07294508

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.